Show simple item record

dc.contributor.authorArif, Sefina
dc.contributor.authorLeete, Pia
dc.contributor.authorNguyen, Vy
dc.contributor.authorMarks, Katherine
dc.contributor.authorNor, Nurhanani Mohamed
dc.contributor.authorEstorninho, Megan
dc.contributor.authorKronenberg-Versteeg, Deborah
dc.contributor.authorBingley, Polly J.
dc.contributor.authorTodd, John A.
dc.contributor.authorGuy, Catherine
dc.contributor.authorDunger, David B.
dc.contributor.authorPowrie, Jake
dc.contributor.authorWillcox, A
dc.contributor.authorFoulis, Alan K.
dc.contributor.authorRichardson, Sarah J.
dc.contributor.authorde Rinaldis, Emanuele
dc.contributor.authorMorgan, Noel G.
dc.contributor.authorLorenc, Anna
dc.contributor.authorPeakman, Mark
dc.date.accessioned2015-07-28T10:39:54Z
dc.date.issued2014-06-17
dc.description.abstractStudies in type 1 diabetes indicate potential disease heterogeneity, notably in the rate of β-cell loss, responsiveness to immunotherapies, and, in limited studies, islet pathology. We sought evidence for different immunological phenotypes using two approaches. First, we defined blood autoimmune response phenotypes by combinatorial, multiparameter analysis of autoantibodies and autoreactive T-cell responses in 33 children/adolescents with newly diagnosed diabetes. Multidimensional cluster analysis showed two equal-sized patient agglomerations characterized by proinflammatory (interferon-γ-positive, multiautoantibody-positive) and partially regulated (interleukin-10-positive, pauci-autoantibody-positive) responses. Multiautoantibody-positive nondiabetic siblings at high risk of disease progression showed similar clustering. Additionally, pancreas samples obtained post mortem from a separate cohort of 21 children/adolescents with recently diagnosed type 1 diabetes were examined immunohistologically. This revealed two distinct types of insulitic lesions distinguishable by the degree of cellular infiltrate and presence of B cells that we termed "hyper-immune CD20Hi" and "pauci-immune CD20Lo." Of note, subjects had only one infiltration phenotype and were partitioned by this into two equal-sized groups that differed significantly by age at diagnosis, with hyper-immune CD20Hi subjects being 5 years younger. These data indicate potentially related islet and blood autoimmune response phenotypes that coincide with and precede disease. We conclude that different immunopathological processes (endotypes) may underlie type 1 diabetes, carrying important implications for treatment and prevention strategies.en_GB
dc.description.sponsorshipJDRFen_GB
dc.description.sponsorshipNational Institute for Health Research (NIHR) Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College Londonen_GB
dc.description.sponsorshipEuropean Union (EU FP7) award - Persistent Virus Infection in Diabetes Network Study Group (PEVNET)en_GB
dc.description.sponsorshipEU FP7 Large-Scale Focused Collaborative Research Project on Natural Immunomodulators as Novel Immunotherapies for Type 1 Diabetes (NAIMIT)en_GB
dc.description.sponsorshipEU FP7 Large-Scale Focused Collaborative Research Project on β-cell preservation through antigen-specific immunotherapy in Type 1 Diabetes: Enhanced Epidermal Antigen Delivery Systems (EE-ASI)en_GB
dc.description.sponsorshipNational Institutes of Health (NIH)en_GB
dc.description.sponsorshipNational Institute of Diabetes and Digestive and Kidney Diseasesen_GB
dc.description.sponsorshipNational Institute of Allergy and Infectious Diseasesen_GB
dc.description.sponsorshipEunice Kennedy Shriver National Institute of Child Health and Human Developmenten_GB
dc.description.sponsorshipNational Center for Research Resourcesen_GB
dc.description.sponsorshipGeneral Clinical Research Centeren_GB
dc.description.sponsorshipAmerican Diabetes Association (ADA)en_GB
dc.identifier.citationVol. 63 (11), pp. 3835 - 3845en_GB
dc.identifier.doi10.2337/db14-0365
dc.identifier.grantnumber1-2007-1803en_GB
dc.identifier.grantnumber261441en_GB
dc.identifier.grantnumber241447en_GB
dc.identifier.grantnumber305305en_GB
dc.identifier.grantnumber01-DK-061010en_GB
dc.identifier.grantnumberU01-DK-061016en_GB
dc.identifier.grantnumberU01-DK-061034en_GB
dc.identifier.grantnumberU01-DK-061036en_GB
dc.identifier.grantnumberU01-DK-061040en_GB
dc.identifier.grantnumberU01-DK-061041en_GB
dc.identifier.grantnumberU01-DK-061042en_GB
dc.identifier.grantnumberU01-DK-061055en_GB
dc.identifier.grantnumberU01-DK-061058en_GB
dc.identifier.grantnumberU01-DK-084565en_GB
dc.identifier.grantnumberU01-DK-085453en_GB
dc.identifier.grantnumberU01-DK-085461en_GB
dc.identifier.grantnumberU01-DK-085463en_GB
dc.identifier.grantnumberU01-DK-085466en_GB
dc.identifier.grantnumberU01-DK-085499en_GB
dc.identifier.grantnumberU01-DK-085505en_GB
dc.identifier.grantnumberU01-DK-085509en_GB
dc.identifier.grantnumberHHSN267200800019Cen_GB
dc.identifier.grantnumberUL1-RR-024131en_GB
dc.identifier.grantnumberUL1-RR-024139en_GB
dc.identifier.grantnumberUL1-RR-024153en_GB
dc.identifier.grantnumberUL1-RR-024975en_GB
dc.identifier.grantnumberUL1-RR-024982en_GB
dc.identifier.grantnumberUL1-RR-025744en_GB
dc.identifier.grantnumberUL1-RR-025761en_GB
dc.identifier.grantnumberUL1-RR-025780en_GB
dc.identifier.grantnumberUL1-RR-029890en_GB
dc.identifier.grantnumberUL1-RR-031986en_GB
dc.identifier.grantnumberM01-RR-00400en_GB
dc.identifier.urihttp://hdl.handle.net/10871/17968
dc.language.isoenen_GB
dc.publisherAmerican Diabetes Associationen_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/24939426en_GB
dc.relation.urlhttp://hdl.handle.net/10871/40335
dc.rightsCopyright © 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.en_GB
dc.subjectAdolescenten_GB
dc.subjectAutoantibodiesen_GB
dc.subjectAutoantigensen_GB
dc.subjectAutoimmunityen_GB
dc.subjectCD4-Positive T-Lymphocytesen_GB
dc.subjectChilden_GB
dc.subjectChild, Preschoolen_GB
dc.subjectDiabetes Mellitus, Type 1en_GB
dc.subjectFemaleen_GB
dc.subjectHumansen_GB
dc.subjectMaleen_GB
dc.titleBlood and islet phenotypes indicate immunological heterogeneity in type 1 diabetesen_GB
dc.typeArticleen_GB
dc.date.available2015-07-28T10:39:54Z
dc.identifier.issn0012-1797
exeter.place-of-publicationUnited States
dc.descriptionThis is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association (ADA), publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version is available in Diabetes in print and online at http://diabetes.diabetesjournals.orgen_GB
dc.descriptionThe erratum to this article is available in ORE at http://hdl.handle.net/10871/40335
dc.identifier.eissn1939-327X
dc.identifier.journalDiabetesen_GB
refterms.dateFOA2020-01-09T14:42:35Z


Files in this item

This item appears in the following Collection(s)

Show simple item record